Fluorine-18-DCFPyL

Drug Profile

Fluorine-18-DCFPyL

Alternative Names: [18F]DCFPyL; DCFPyL-18F; PyL™

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Progenics Pharmaceuticals
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Prostate cancer

Most Recent Events

  • 25 Apr 2017 Progenics Pharmaceuticals has patents pending for fluorine-18-DCFPyL worldwide
  • 09 Mar 2017 Progenics Pharmaceuticals has patent protection for fluorine-18-DCFPyL in USA and countries outside USA
  • 09 Jan 2017 Phase-II clinical trials in Prostate cancer (Diagnosis) in Canada (IV) (NCT02793284)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top